GenMark Diagnostics, Inc.
If you purchased GenMark Diagnostics, Inc. securities and would like to join the action, please click "Join This Action" below.
GENMARK MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF GENMARK DIAGNOSTICS, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – GNMK
March 15, 2021.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of GenMark Diagnostics, Inc. (NASDAQ: GNMK) to Roche is fair to GenMark shareholders. Under the terms of the merger agreement, Roche will acquire all outstanding shares of GenMark common stock for $24.05 per share in cash.
The investigation concerns whether GenMark and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for GenMark shareholders; (2) determine whether Roche is underpaying for GenMark; and (3) disclose all material information necessary for GenMark shareholders to adequately assess and value the merger consideration. On behalf of GenMark shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.